BAX and liver cancer: Considering EF24’s inhibition of ERK 1/2, upregulation of activated caspase-3, and alteration of Bax/Bcl-2 and Bax/Bcl-xL ratios [33], [36], we examined the therapeutic potential and molecular mechanisms of EF24 on liver cancer cells.